Low-risk breast cancer patients who opt for accelerated partial breast radiotherapy—a one-week alternative to traditional whole-breast radiotherapy—see the same quality of life as women who undergo conventional treatment, researchers reported at this year’s European Society for Radiotherapy and Oncology (ESTRO) Congress.
Shorter courses of radiotherapy for prostate cancer are safe and effective, a study has found, saving patients time and potentially reducing waiting lists. Researchers found that higher doses of “ultra-hypofractionated” radiotherapy every other day for two and a half weeks worked as well as standard radiotherapy given every week day for eight weeks.
With the advent of personalised cancer medicine, patients may not always receive the most effective treatment in their particular case. In a bid to put this situation to rights, the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) have joined forces to launch a new initiative, E2-RADIatE (EORTC-ESTRO Radiation Infrastructure for Europe). The project will be presented for the first time at the ESTRO 37 conference.
n analysis of elderly patients treated in a phase II trial of radiotherapy combined with chemotherapy in non-small cell lung cancer has shown that they were less likely to benefit than younger patients if the two treatments were given at the same time.
Hundreds of people across Cumbria did not start treatment for cancer within the government set target of two months last year. The situation was worst in the north of the county, where health services are commissioned on behalf of residents by North Cumbria Clinical Commissioning Group.
The new Cancer Research UK Centre of Excellence in Cambridge and London aims to improve treatment and survival rates. Professor Richard Gilbertson is leading the biggest push yet to bring about a major change in survival rates as director of the new Cancer Research UK Children’s Brain Tumour Centre of Excellence at the University of Cambridge and the ICR (Institute for Cancer Research) in London.
Very small differences in the way a patient lies during radiotherapy treatment for lung or oesophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference.
New research presented at the ESTRO 37 conference today (Saturday) from two large international trials, shows that intra-cavitary and interstitial brachytherapy is safe and does not increase the risk of ureteral stricture.
Quality of life for women treated with a more targeted radiotherapy treatment – called accelerated partial breast irradiation – is at least as good as quality of life for women treated with standard radiotherapy, according to research presented at the ESTRO 37 conference and published simultaneously in The Lancet Oncology.
South Lakes MP Tim Farron will chair a national meeting this week to discuss how to improve access to cancer services across the country. Attending the meeting, which takes place in Westminster next Wednesday, will be leading professionals including clinicians, scientists and cancer treatment manufacturers. Tim will be chairing the meeting in his capacity as a patron of the leading cancer charity Action Radiotherapy.